Globally, cancer patients frequently use T&CM during their treatment for various reasons. The primary concerns regarding the use of T&CM among cancer patients are the potential risks associated with interactions between pharmaceuticals and T&CM, as well as the risk of noncompliance with conventional cancer treatments. Despite the higher prevalence of T&CM use in Asia, driven by cultural, historical, and resource-related factors, no prior review has tried to estimate the prevalence and influencing factors of T&CM use and disclosure among cancer patients in this region. This study aims to examine the prevalence and disclosure rates of T&CM use among cancer patients in Asia to assess various factors influencing its use across different cancer treatment settings in Asia. Systematic research on T&CM use was conducted using four databases (PubMed, EMBASE, Web of Science, and CINAHAL) from inception to January 2023. Quality was assessed using the Appraisal Tool for Cross-Sectional Studies (AXIS). A random effects model was used to estimate the pooled prevalence of T&CM use, and data analysis was performed using Stata Version 16.0. Among the 4849 records retrieved, 41 eligible studies conducted in 14 Asian countries were included, involving a total of 14,976 participants. The pooled prevalence of T&CM use was 49.3%, ranging from 24.0% to 94.8%, and the disclosure rate of T&CM use was 38.2% (11.9% to 82.5%). The most commonly used T&CM modalities were herbal medicines and traditional medicine. Females were 22.0% more likely to use T&CM than males. A subgroup analysis revealed the highest prevalence of T&CM use was found in studies conducted in East Asia (62.4%) and those covered by both national and private insurance (55.8%). The disclosure rate of T&CM use to physicians remains low. Moreover, the factors influencing this disclosure are still insufficiently explored. Since the disclosure of T&CM use is a crucial indicator of patient safety and the quality of cancer treatment prognosis, future research should focus on identifying the determinants of non-disclosure.
在全球范围内，癌症患者出于多种原因在治疗过程中频繁使用传统与补充医学。关于癌症患者使用传统与补充医学的主要担忧，涉及药物与传统补充医学之间相互作用的潜在风险，以及不遵从常规癌症治疗的风险。尽管在文化、历史和资源相关因素的驱动下，亚洲地区传统与补充医学的使用更为普遍，但此前尚无综述尝试评估该地区癌症患者使用及告知传统与补充医学的普遍程度及其影响因素。本研究旨在考察亚洲癌症患者使用传统与补充医学的普遍程度及告知率，以评估亚洲不同癌症治疗环境中影响其使用的各种因素。通过使用四个数据库（PubMed、EMBASE、Web of Science和CINAHAL），对从建库至2023年1月期间关于传统与补充医学使用的文献进行了系统研究。研究质量使用横断面研究评估工具进行评估。采用随机效应模型估计传统与补充医学使用的汇总普遍程度，并使用Stata 16.0版进行数据分析。在检索到的4849条记录中，纳入了在14个亚洲国家进行的41项符合条件的研究，共涉及14,976名参与者。传统与补充医学使用的汇总普遍程度为49.3%，范围从24.0%到94.8%，而传统与补充医学使用的告知率为38.2%（11.9%至82.5%）。最常用的传统与补充医学形式是草药和传统医学。女性使用传统与补充医学的可能性比男性高22.0%。亚组分析显示，在东亚进行的研究（62.4%）以及同时涵盖国家和私人保险的研究（55.8%）中，传统与补充医学的使用普遍程度最高。向医生告知传统与补充医学使用的情况仍然较少。此外，影响这种告知的因素仍未得到充分探讨。由于告知传统与补充医学的使用是患者安全和癌症治疗预后质量的关键指标，未来的研究应侧重于确定不告知的决定因素。
肿瘤(癌症)患者之家